New regimens and new medications in the treatment of tuberculosis: keeping step?
Open Access
- 1 January 2021
- journal article
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 23 (1)
- https://doi.org/10.36488/cmac.2021.1.27-42
Abstract
Rapid tests detecting Mycobacterium tuberculosis and drug resistance which are universally implemented in medical practice has dramatically improved the diagnosis of rifampicin-resistant tuberculosis and shortened turnaround time thus enabling early etiotropic therapy. However, permanently increasing drug resistance of M. tuberculosis makes treatment less effective. Furthermore, long treatment courses are required due to low sterilizing activity of treatment regimens used for drug-resistant tuberculosis which leads to greater toxic effects, reduces patients’ adherence to treatment and consumes resources of medical care systems. Current phthisiology needs new effective medications and short treatment regimens, otherwise elimination of tuberculosis by 2050 is impossible. This review summarizes the information about treatment of drugresistant TB, including repurposed drugs, new medications and treatment regimens.Keywords
This publication has 58 references indexed in Scilit:
- Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis PatientsPLOS ONE, 2013
- Supporting TB clinicians managing difficult cases: the ERS/WHO ConsiliumEuropean Respiratory Journal, 2013
- Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosisEuropean Respiratory Journal, 2012
- Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TBEuropean Respiratory Journal, 2012
- New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the FutureThe Journal of Infectious Diseases, 2012
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohortThe Lancet, 2010
- Synthesis and Antituberculosis Activity of a Novel Series of Optically Active 6-Nitro-2,3-dihydroimidazo[2,1-b]oxazolesJournal of Medicinal Chemistry, 2006
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLoS Medicine, 2006
- Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosisDiagnostic Microbiology and Infectious Disease, 1991